Samsung Bioepis Launches Ranibizumab In Korea
Partner Samil Introduces Amelivu Biosimilar Rival To Lucentis
Executive Summary
Samsung Bioepis has announced the launch of its SB11 ranibizumab biosimilar rival to Lucentis in Korea through partner Samil. The introduction – under the name Amelivu – comes after the product was launched as Byooviz in the US last year.